Khan MAB, Hashim MJ, King JK, Govender RD, Mustafa H, Al Kaabi J. Epidemiology of type 2 diabetes – global burden of disease and forecasted trends. J Epidemiol Glob Health. 2020;10(1):107-11. https://pubmed.ncbi.nlm.nih.gov/32175717. PMCID: PMC7310804. https://doi.org/10.2991/jegh.k.191028.001.

International Diabetes Federation. Diabetes Atlas, 10th ed. https://diabetesatlas.org/. Accessed December 2, 2022.

Republic of the Philippines National Nutrition Council. The obesity epidemic.. Accessed December 2, 2022.

Ma RC, Chan JC. Type 2 diabetes in East Asians: similarities and differences with populations in Europe and the United States. Ann N Y Acad Sci. 2013;1281(1):64-91. https://pubmed.ncbi.nlm.nih.gov/23551121. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3708105. https://doi.org/10.1111/nyas.12098.

Paz-Pacheco E, Jimeno C. Diabetes care in the Philippines. J ASEAN Fed Endocr Soc. 2015;30(2):118. https://doi.org/10.15605/jafes.030.02.17.

Fojas MC, Lantion-Ang FL, Jimeno CA, et al. Complications and cardiovascular risk factors among newly-diagnosed type 2 diabetics in Manila. Philipp J Int Med. 2009:47(3);99-105. https://drive.google.com/file/d/1KzdeGegJwEn-lPx7-U0tZMAbTKoFZL_P/view.

Shah A, Kanaya AM. Diabetes and associated complications in the South Asian population. Curr Cardiol Rep. 2014;16:476. https://pubmed.ncbi.nlm.nih.gov/24643902. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC40263322014. https://doi.org/10.1007/s11886-014-0476-5.

Tan GH. Diabetes care in the Philippines. Ann Glob Health. 2015;81(6):863-9. https://pubmed.ncbi.nlm.nih.gov/27108153. https://doi.org/10.1016/j.aogh.2015.10.004.

Jimeno C, Sobrepena LM, Mirasol RC. DiabCare 2008: Survey on glycaemic control and the status of diabetes care and complications among patients with type 2 diabetes mellitus in the Philippines. Philipp J Int Med. 2012;50(1):15-22.

Jimeno C, Sy RA, De la Pena P, et al. Direct medical costs of type 2 diabetes mellitus in the Philippines: findings from two hospital databases and physician surveys. BMJ Open. 2021;11:e049737. https://pubmed.ncbi.nlm.nih.gov/34635519. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8506878. https://doi.org/10.1136/bmjopen-2021-049737.

Eala MAB, Besa JJ, Mag-Usara RCQ, Arcellana AES, Jimeno CA. Access to insulin and diabetes care in the Philippines. Lancet Diabetes Endocrinol. 2022;10(1):16. https://pubmed.ncbi.nlm.nih.gov/34826392. https://doi.org/10.1016/S2213-8587(21)00309-0.

Republic of the Philippines Department of Health. What is insulin access program? https://www.doh.gov.ph/faqs/What-is-Insulin-Access-Program. Accessed December 2, 2022.

Republic of the Philippines Department of Health. [Department Circular No 2022–0537] Health Technology Assessment Council (HTAC) Recommendation for the inclusion of insulin glargine and non inclusion of insulin determir for patients with type 1 or type 2 diabetes mellitus in the Philippine National Formulary (PNF). 2022. https://hta.dost.gov.ph/department-circular-no-2022-0537-health-technology-assessment-council-htac-recommendation-for-the-inclusion-of-insulin-glargine-and-non-inclusion-of-insulin-detemir-for-patients-with-type-1-or/. Accessed December 2, 2022.

Republic of the Philippines Department of Health. The Philippine National Formulary. https://pharma.doh.gov.ph/the-philippine-national-formulary/. Accessed January 10, 2023.

Lambojon K, Chang J, Saeed A, et al. Prices, availability and affordability of medicines with value-added tax exemption: A cross-sectional survey in the Philippines. Int J Environ Res Public Health. 2020;17(14):5242. https://pubmed.ncbi.nlm.nih.gov/32708060. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7400398. https://doi.org/10.3390/ijerph17145242.

Ryzodeg® Summary of product characteristics; 2017. https://www.ema.europa.eu/en/documents/product-information/ryzodeg-epar-product-information_en.pdf. Accessed December 2, 2022

Franek E, Haluzík M, Canecki Varžić S, et al. Twice daily insulin degludec/insulin aspart provides superior fasting plasma glucose control and a reduced rate of hypoglycaemia compared with biphasic insulin aspart 30 in insulin naïve adults with type 2 diabetes. Diabet Med. 2016;497-505. https://pubmed.ncbi.nlm.nih.gov/26435365. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5063147. https://doi.org/10.1111/dme.12982.

Kaneko S, Chow F, Choi DS, et al. Insulin degludec/insulin aspart versus biphasic insulin aspart 30 in Asian patients with type 2 diabetes inadequately controlled on basal or pre-/self-mixed insulin: A 26-week, randomised, treat-to-target trial. Diabetes Res Clin Pract. 2015;107(1):139-47. Phttps://pubmed.ncbi.nlm.nih.gov/25498130. https://doi.org/10.1016/j.diabres.2014.09.026.

Rodbard HW, Cariou B, Pieber TR, Endahl LA, Zacho J, Cooper JG. Treatment intensification with an insulin degludec (IDeg)/insulin aspart (IAsp) co formulation twice daily compared with basal IDeg and prandial IAsp in type 2 diabetes: A randomized, controlled phase III trial. Diabetes Obes Metab. 2016;18(3):274-80. https://pubmed.ncbi.nlm.nih.gov/26592732. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5066701. https://doi.org/10.1111/dom.12609.

Onishi Y, Ono Y, Rabøl R, Endahl L, Nakamura S. Superior glycaemic control with once-daily insulin degludec/insulin aspart versus insulin glargine in Japanese adults with type 2 diabetes inadequately controlled with oral drugs: a randomized, controlled phase 3 trial. Diabetes Obes Metab. 2013;15(9):826-32. https://pubmed.ncbi.nlm.nih.gov/23557077. https://doi.org/10.1111/dom.12097.

Shigiyama F, Liu L, Nordahl H, Suzuki R, Yamamoto Y, Hirose T. A real-world, prospective, non-interventional study of adults with T2D switching to IDegAsp from glargine U100 or U300 in Japan. Diabetes Ther. 2021;12(9):2405-21. https://pubmed.ncbi.nlm.nih.gov/34304385. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8385001. https://doi.org/10.1007/s13300-021-01117-8.

Özçelik S, Çelik M, Vural A, Aydın B, Özçelik M, Gozu H. Outcomes of transition from premixed and intensive insulin therapies to insulin aspart/degludec co formulation in type 2 diabetes mellitus: a real-world experience. Arch Med Sci. 2021;17(1):1–8. https://pubmed.ncbi.nlm.nih.gov/33488849. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7811302. https://doi.org/10.5114/aoms.2020.93264.

Fulcher GR, Akhtar S, Al-Jaser SJ, et al. Initiating or switching to insulin degludec/insulin aspart in adults with type 2 diabetes: A real-world, prospective, non interventional study across six countries. Adv Ther. 2022;39(8):3735-48. https://pubmed.ncbi.nlm.nih.gov/35752730. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9244059. https://doi.org/10.1007/s12325-022-02212-3.

Fulcher GR, Jarlov H, Piltoft JS, et al. ARISE—a prospective, non-interventional, single-arm study assessing clinical parameters associated with the use of insulin degludec/insulin aspart in patients with type 2 diabetes in real-world settings: Rationale and design. Endocrine. 2021;74(3):530-7. https://pubmed.ncbi.nlm.nih.gov/34637072. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8506473. https://doi.org/10.1007/s12020-021-02887-8.

ClinicalTrials.gov. Identifier NCT04042441. A research study, looking at how Ryzodeg® (insulin degludec/insulin aspart) works in people with type 2 diabetes in local clinical practice (ARISE). https://clinicaltrials.gov/ct2/show/NCT04042441. Accessed 10 December 2022.

Alvarenga MA, Komatsu WR, de Sa JR, Chacra AR, Dib SA. Clinical inertia on insulin treatment intensification in type 2 diabetes mellitus patients of a tertiary public diabetes center with limited pharmacologic armamentarium from an upper-middle income country. Diabetol Metab Syndr. 2018;10:77. https://pubmed.ncbi.nlm.nih.gov/30386438. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6206856. https://doi.org/10.1186/s13098-018-0382-x

Jabbar A, Mohamed WM, Ozaki R, et al. Patterns and trends in insulin initiation and intensification among patients with type 2 diabetes mellitus in the Western Pacific region. Curr Med Res Opin. 2018;34(9):1653-62. https://pubmed.ncbi.nlm.nih.gov/29863422. http://doi.org/10.1080/03007995.2018.1484712.

Reid T, Gao L, Gill J, et al. How much is too much? Outcomes in patients using high dose insulin glargine. Int J Clin Pract. 2016;70(1):56-65. https://pubmed.ncbi.nlm.nih.gov/26566714. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4738456. https://doi.org/10.1111/ijcp.12747.

Evans M, Schumm-Draeger PM, Vora J, King AB. A review of modern insulin analogue pharmacokinetic and pharmacodynamic profiles in type 2 diabetes: Improvements and limitations. Diabetes Obes Metab. 2011;13(8):677-84. https://pubmed.ncbi.nlm.nih.gov/21410860. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3380549. https://doi.org/10.1111/j.1463-1326.2011.01395.x.

Rizvi AA. Treatment of type 2 diabetes with biphasic insulin analogues. Eur Med J Diabetes. 2016;4(1):74-83. https://pubmed.ncbi.nlm.nih.gov/27918600. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5134918.

Peyrot M, Barnett AH, Meneghini LF, Schumm-Draeger PM. Insulin adherence behaviours and barriers in the multinational global attitudes of patients and physicians in insulin therapy study. Diabet Med. 2012;29(5):682-9. https://pubmed.ncbi.nlm.nih.gov/22313123. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3433794. https://doi.org/10.1111/j.1464-5491.2012.03605.x.

Apovian CM, Okemah J, O’Neil PM. Body weight considerations in the management of type 2 diabetes. Adv Ther. 2019;36(1):44-58. https://pubmed.ncbi.nlm.nih.gov/30465123. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6318231. https://doi.org/10.1007/s12325-018-0824-8.

Kalra S, Aamir AH, Raza A, et al. Place of sulfonylureas in the management of type 2 diabetes mellitus in South Asia: A consensus statement. Indian J Endocrinol Metab. 2015;19(5):577-96. https://pubmed.ncbi.nlm.nih.gov/26425465. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4566336. https://doi.org/10.4103/2230-8210.163171.

Umpierrez GE, Skolnik N, Dex T, Traylor L, Chao J, Shaefer C. When basal insulin is not enough: A dose–response relationship between insulin glargine 100 units/mL and glycaemic control. Diabetes Obes Metab. 2019;21(6):1305-10. https://pubmed.ncbi.nlm.nih.gov/30724009. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6594069. https://doi.org/10.1111/dom.13653.

Higuchi M. Access to diabetes care and medicines in the Philippines. Asia Pac J Public Health. 2010;22(Suppl. 3):96S-102S. https://pubmed.ncbi.nlm.nih.gov/20566540. https://doi.org/10.1177/1010539510373005.

World Health Organization. UHC Act in the Philippines: A new dawn for health care. https://www.who.int/philippines/news/feature-stories/detail/uhc-act-in-the-philippines-a-new-dawn-for-health-care. Accessed December 2, 2022.